Renal Business Today

Watson Pharmaceuticals

FDA Approves Generic Ferrlecit

MORRISTOWN, N.J.—The U.S. Food and Drug Administration (FDA) has approved GeneraMedix Inc.’s generic version of sanofi aventis’ iron drug Ferrlecit. ...More
March 31, 2011
Posted in News, Clinical & Pharma, Government & Regulation
Genzyme Sues Watson Over Generic Renvela Application

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. said July 12 that it has submitted an application to the U.S. Food and Drug Administration to approve a generic form of Genzyme’s phosphate binder Renvela. ...More
July 13, 2010
Posted in News, Government & Regulation
Future Iron Treatments Shaped by New Payment Structures, Products

The choice of what iron product to use will be especially relevant with the bundled payment set to start in 2011. According to an August 2009 BioTrends report, dialysis clinic medical directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen’s ...More
January 29, 2010
Posted in Articles, Business, Clinical & Pharma, Practice Management
Watson, GeneraMedix to Market Generic Ferrlecit

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. announced July 29 a license agreement with GeneraMedix Inc., for the exclusive U.S. marketing rights to a generic version of Ferrlecit, a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients ...More
July 29, 2009
Posted in News, Business, Clinical & Pharma
Watson CFO Takes Leave of Absence

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. announced July 27 that Mark W. Durand, senior vice president and chief financial officer, has taken a leave of absence from the company for health reasons. ...More
July 27, 2009
Posted in News, Business, Clinical & Pharma
Watson to Keep Selling Ferrlecit Until End of Year

CORONA, Calif.—Watson Pharmaceuticals said May 18 it will continue to sell the iron deficiency treatment Ferrlecit in the United States until the end of the year after a Swiss arbiter ruled in favor of the company. ...More
May 18, 2009
Posted in News, Business, Clinical & Pharma, Practice Management
U.S. regulators question Fresenius IV iron deal, set reimbursement terms

WASHINGTON—Before approving a deal in which dialysis provider Fresenius Medical Care obtained exclusive licensing rights to the drug Venofer, the U.S. Federal Trade Commission (FTC) raised competition concerns and set terms under which Fresenius wouldn’t be able to ...More
September 16, 2008
Posted in News, Business, Clinical & Pharma
Anemia managers placing more emphasis on IV iron

EXTON, Pa.— Anemia managers for dialysis patients are more likely to report that they are using lower average doses of erythropoiesis-stimulating agents, monitoring hemoglobins more frequently and placing more emphasis on a patient's IV iron status, according to a report ...More
September 12, 2008
Posted in News, Business, Clinical & Pharma
What's Next in Dialysis Iron Management?

Iron is on the minds of many Americans, especially with the superhero movie “Iron Man” raking in $100 million its first weekend in theatres. But hundreds of thousands of people have other reasons to think about iron, as it is a vital nutrient dialysis patients ...More
May 21, 2008
Posted in Articles, Business, Clinical & Pharma

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Watson Pharmaceuticals

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail